{"organizations": [], "uuid": "7d5a3a623ab15e6358e9239217e2ad315679ed67", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-helix-biopharma-corp-announces-reg/brief-helix-biopharma-corp-announces-regulatory-approval-to-dose-patients-in-a-phase-ii-randomized-study-of-l-dos47-with-vinorelbine-and-cisplatin-idUSFWN1RN07Z", "country": "US", "domain_rank": 408, "title": "BRIEF-Helix Biopharma Corp. Announces Regulatory Approval To Dose Patients In A Phase II Randomized Study of L-DOS47 With Vinorelbine And Cisplatin", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-10T14:45:00.000+03:00", "replies_count": 0, "uuid": "7d5a3a623ab15e6358e9239217e2ad315679ed67"}, "author": "", "url": "https://www.reuters.com/article/brief-helix-biopharma-corp-announces-reg/brief-helix-biopharma-corp-announces-regulatory-approval-to-dose-patients-in-a-phase-ii-randomized-study-of-l-dos47-with-vinorelbine-and-cisplatin-idUSFWN1RN07Z", "ord_in_thread": 0, "title": "BRIEF-Helix Biopharma Corp. Announces Regulatory Approval To Dose Patients In A Phase II Randomized Study of L-DOS47 With Vinorelbine And Cisplatin", "locations": [], "entities": {"persons": [], "locations": [{"name": "ukraine", "sentiment": "none"}], "organizations": [{"name": "brief-helix biopharma corp", "sentiment": "negative"}, {"name": "vinorelbine and cisplatin reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "helix biopharma corp", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "biopharma corp", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Market News April 10, 2018 / 11:47 AM / in 8 minutes BRIEF-Helix Biopharma Corp. Announces Regulatory Approval To Dose Patients In A Phase II Randomized Study of L-DOS47 With Vinorelbine And Cisplatin Reuters Staff 1 Min Read \nApril 10 (Reuters) - Helix Biopharma Corp: \n* HELIX BIOPHARMA CORP. ANNOUNCES REGULATORY APPROVAL TO DOSE PATIENTS IN A PHASE II RANDOMIZED STUDY OF L-DOS47 WITH VINORELBINE AND CISPLATIN \n* ALL NECESSARY REGULATORY AND ETHICS APPROVALS HAVE BEEN RECEIVED TO DOSE FIRST PATIENT IN ITS LDOS003 TRIAL IN UKRAINE Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-10T14:45:00.000+03:00", "crawled": "2018-04-10T15:06:54.011+03:00", "highlightTitle": ""}